On Monday, Shares of Sysco Corporation (NYSE:SYY), gained 1.79% to $37.59.
Sysco Corporation declared financial results for its fourth quarter and fiscal year ended June 27, 2015.
Fourth Quarter Fiscal 2015 Highlights
- Sales raised 0.9% to $12.4 billion;
- Gross profit raised 3.0% to $2.2 billion; gross margin raised 35 basis points to 17.9%;
- Adjusted operating income raised 5.8% to $509 million; and
- Adjusted EPS raised 6.1% to $0.52.
Fiscal 2015 Highlights
- Sales raised 4.7% to $48.7 billion;
- Gross profit raised 4.5% to $8.6 billion; gross margin was flat at 17.6%;
- Adjusted operating income raised 3.4% to $1.8 billion;
- Adjusted EPS raised 5.1% to $1.84; and
- Cash flow from operations was $1.6 billion; and free cash flow was $1.0 billion.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry.
Shares of Spectra Energy Corp. (NYSE:SE), inclined 4.23% to $30.05, during its last trading session.
Spectra Energy Corp, declared that the board of directors of its general partner declared a quarterly cash distribution to unitholders of $0.61375 per unit, an enhance of 1.25 cents over the previous level of $0.60125 per unit. This is the 31st successive quarter that Spectra Energy Partners has raised its quarterly cash distribution. The cash distribution is payable on August 28, 2015, to unitholders of record at the close of business on August 14, 2015. This quarterly cash distribution equates to $2.455 per unit on an annual basis.
Spectra Energy Corp, through its auxiliaries, owns and operates a portfolio of natural gas-related energy assets in North America. The company’s Spectra Energy Partners segment engages in the transmission, storage, and gathering of natural gas, in addition to transportation and storage of crude oil and natural gas liquids (NGLs) for customers in various regions of the midwestern, northeastern, and southeastern United States and Canada.
Finally, Opko Health, Inc. (NYSE:OPK), ended its last trade with 0.73% gain, and closed at $13.86.
OPKO Health declared that additional data from OPKO’s hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, “12 month Safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) contrast to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary” and “Pharmacokinetic (PK) and Pharmacodynamics (PD) Modeling of MOD 4023 (a long-acting human growth hormone (hGH)) in Growth Hormone Deficient (GHD) Children” has been selected for oral presentation at the forthcoming 54th Annual Meeting of the European Society for Paediatric Endocrinology taking place in Barcelona, Spain from October 1-3.
The data to be presented comprise results for 52 patients concluding twelve months of weekly treatment with hGH-CTP. This phase 2 study was a one year, dose finding study administering hGH-CTP to growth hormone deficient children once a week using Genotropin® administered daily as a comparator arm. The twelve months data confirm comparable response of hGH-CTP to Genotropin® injected daily as reflected by the twelve months serum insulin-like growth factor-1 standard deviation score (IGF-1SDS) profile, annual height velocity (HV), height velocity standard deviation score (HV SDS) and safety profile. The data affirm the selection of an optimal dose that would be used to demonstrate non-inferiority contrast to daily administered hGH in the forthcoming phase 3 study.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
